VICORE PHARMA HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.45 SEK | +2.76% |
|
+6.29% | +44.22% |
| May. 07 | Vicore Pharma Holding AB Announces Board Appointments | CI |
| May. 03 | Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 52M 4.8M | Sales 2025 * | 393M 36.26M | Capitalization | 2.28B 211M |
|---|---|---|---|---|---|
| Net income 2024 * | -223M -20.57M | Net income 2025 * | -173M -15.96M | EV / Sales 2024 * | 38.1 x |
| Net cash position 2024 * | 304M 28.08M | Net cash position 2025 * | 210M 19.38M | EV / Sales 2025 * | 5.28 x |
| P/E ratio 2024 * |
-14.9
x | P/E ratio 2025 * |
-8.69
x | Employees | 24 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.02% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vicore Pharma Holding AB
More press releases
| 1 day | +2.76% | ||
| 1 week | +6.29% | ||
| Current month | +13.23% | ||
| 1 month | +12.49% | ||
| 3 months | +35.43% | ||
| 6 months | +54.92% | ||
| Current year | +44.22% |
1 week
19.26
21.05
1 month
15.6421.05
Current year
12.8421.05
1 year
12.3626.90
3 years
12.2037.45
5 years
6.8238.30
10 years
5.7040.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ahmed Mousa
CEO | Chief Executive Officer | 40 | 23-09-08 |
Hans Jeppsson
DFI | Director of Finance/CFO | - | 16-12-31 |
Elin Rosendahl
CTO | Chief Tech/Sci/R&D Officer | - | 20-11-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 57 | 17-12-31 | |
| Chairman | 66 | 17-12-31 | |
Michael Buschle
BRD | Director/Board Member | 64 | 22-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 20.45 | +2.76% | 385,025 |
| 24-05-08 | 19.9 | -0.75% | 140,473 |
| 24-05-07 | 20.05 | +1.67% | 135,802 |
| 24-05-06 | 19.72 | +2.49% | 193,997 |
| 24-05-03 | 19.24 | +1.91% | 402,894 |
Delayed Quote Nasdaq Stockholm, May 10, 2024 at 11:29 am EDT
More quotes
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Calendar
2024-05-16
- American Thoracic Society Conference
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
20.45
SEK
Average target price
61.5
SEK
Spread / Average Target
+200.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.22% | 211M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- VICO Stock
